Thirty patients with caudate lobe HCC were treated to a total doses of 55 to 77 (median 72.6) GyRBE. The median follow-up period was 37.5 months. The OS rates at 1-, 3- and 5-year were 86.6%, 62.8% and 46.1%, respectively, and the LC rates of 100%, 85.9% and 85.9%, respectively. No grade 3 or worse adverse events were observed. PBT is effective and safe for the treatment of caudate HCC, should therefore be considered a feasible option for intervention in patients with this disease.